As targeting NF-κB enhances response to RAF inhibitors [66] and targeting MITF along with HDAC prevents cAMP/MITF-driven resistance to MAPK-pathway inhibitors [60], PN might be considered as a part of combined therapy for melanoma patients with BRAFV600E-driven melanomas. This evidence concerns the gene MITF and melanoma.